Alamar Biosciences (NASDAQ:ALMR) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Alamar Biosciences (NASDAQ:ALMR) announced its earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03, FiscalAI reports. The business had revenue of $33.55 million for the quarter.

Alamar Biosciences Stock Up 4.4%

ALMR opened at $30.22 on Wednesday. Alamar Biosciences has a 12 month low of $18.84 and a 12 month high of $39.61. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The business has a 50 day simple moving average of $30.49.

Key Stories Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: For Q3 2026, Alamar reported a loss of $0.19 per share, beating the $0.22-per-share loss consensus, and revenue of $33.55 million. The company also raised its 2026 revenue guidance, a potentially supportive signal for its growth outlook. Alamar reports Q3 results and raises 2026 revenue guidance
• Positive Sentiment: Alamar announced a scientific collaboration with GSK using its NULISA platform in a large-scale study of protein signatures across several disease areas. The partnership could raise the platform’s profile, though no financial terms were disclosed. Alamar partners with GSK on proteomic study
• Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study focused on neurodegenerative diseases, with support from major research organizations. The project may showcase Alamar’s technology in a significant research effort; direct commercial impact was not specified. Alamar and Nightingale to lead UK Biobank study
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming disclosed sales totaling 187,636 shares across October 30 and November 2. Large-holder selling can weigh on sentiment, although the filings do not state the reason for the sales. SEC filing on shareholder transactions

Insider Transactions at Alamar Biosciences

In related news, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the sale, the insider directly owned 160,913 shares in the company, valued at approximately $4,801,643.92. The trade was a 21.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 1,387,636 shares of company stock worth $41,234,931.

Institutional Trading of Alamar Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ALMR. China Universal Asset Management Co. Ltd. bought a new position in shares of Alamar Biosciences in the third quarter worth $196,000. Squarepoint Ops LLC purchased a new stake in Alamar Biosciences in the second quarter valued at approximately $283,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after buying an additional 10,461 shares in the last quarter. State Street Corp purchased a new stake in Alamar Biosciences during the second quarter valued at about $3,930,000. Finally, Wellington Management Group LLP bought a new stake in Alamar Biosciences in the 2nd quarter worth approximately $12,407,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALMR. Stifel Nicolaus boosted their price target on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Finally, Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alamar Biosciences presently has an average rating of “Hold” and a consensus target price of $31.80.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.